Patent · US Active

Controlled-release CNP agonists with increased NEP stability

US11224661B2 · kind B2 · utility

4Cited by

11References

13Claims

0Family size

Assignee

ASCENDIS PHARMA GROWTH DISORDERS A/S · DK

Inventors

Kennett Sprogøe · Rudegård, DK
Harald Rau · Würzburg, DE
Ana Bernhard · Heidelberg, DE
Ulrich Hersel · Heidelberg, DE
Felix Cleenmann · Mainz, DE
Thomas Wegge · Heidelberg, DE

Key dates

Filing date	Jan 5, 2017
Grant date	Jan 18, 2022
Priority date	—
Expiry date	Jan 5, 2037

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to controlled-release CNP agonists having an at least 5-fold longer degradation half-life in an in vitro NEP degradation assay than the corresponding released CNP agonist, to pharmaceutical compositions comprising said controlled-release CNP agonist, their use and to methods of treatment.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.